Bayer and Regeneron Start New Trial for Eye Disease Solution

Bayer HealthCare and Regeneron Pharmaceuticals have started a new Phase III clinical trial in Asia to find a cure solution for myopia.

Myopia is a prevalent eye condition in Asian countries such as Singapore and Japan, where around 40% of adults have myopia and nearly 10% of these have high myopia. A new Phase III clinical trial as a treatment study for patients with choroidal neovascularisation (CNV) of the retina as a result of pathologic myopia has been initiated by Bayer HealthCare and Regeneron Pharmaceuticals in Japan.

In collaboration with the Singapore Eye Research Institute (SERI), the trial, named MYRROR, has a goal to investigate the efficacy and safety of VEGF Trap-Eye (aflibercept ophthalmic solution) in patients. The trial will be performed in some other Asian regions including China, Korea Singapore and Taiwan.

Myopic CNV is a complication of high myopia where abno